Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system?


MELEK H., Cetinkaya G., ÖZER E., YENTÜRK E., SEVİNÇ T. E. , BAYRAM A. S. , ...More

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, vol.56, no.3, pp.604-611, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 56 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.1093/ejcts/ezz044
  • Journal Name: EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.604-611
  • Keywords: Pathological complete response, Induction treatment, Neoadjuvant treatment, CHEMOTHERAPY, MANAGEMENT, SURVIVAL, OUTCOMES, SURGERY, THERAPY

Abstract

OBJECTIVES: Prognosis for patients with non-small-cell lung cancer (NSCLC) who, after neoadjuvant/induction and surgery, have a pathological complete response (pCR) is expected to be improved. However, the place of the pCR patients in the context of the tumour, lymph node and metastasis (TNM) staging system is still not defined. The aim of this study is to investigate the long-term survival of NSCLC patients with pCR and to find their appropriate staging category within the TNM staging system.